The recent surge in investments into boutique pharmaceutical companies, particularly those focusing on novel therapies and difficult drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the possibility for game-changing treatments and impressive returns is clear, the linked risks are also considerable. Many o